Comparison
46 Xx Disorder Of Sex Development Induced By Maternal Derived Androgen C5680197 vs 3q26 Microduplication Syndrome C4755319
Clinical comparison between 46 XX Disorder OF Sex Development Induced BY Maternal Derived Androgen and 3q26 Microduplication Syndrome for differential diagnosis and treatment planning.
46 Xx Disorder Of Sex Development Induced By Maternal Derived Androgen C5680197
A condition where androgens from the pregnant person cross to the fetus, causing atypical genital development in an XX baby. It ranges from mild to severe. Specialists guide hormone and surgical management.
3q26 Microduplication Syndrome C4755319
A genetic condition involving extra genetic material at chromosome 3q26, which can cause developmental delays and other features depending on specific genes involved.
6 comparison axes
Onset
46 Xx Disorder Of Sex Development Induced By Maternal Derived Androgen C5680197
0-0
3q26 Microduplication Syndrome C4755319
0-null
Onset patterns differ
Severity
46 Xx Disorder Of Sex Development Induced By Maternal Derived Androgen C5680197
severe
3q26 Microduplication Syndrome C4755319
moderate
Different severity levels
Chronic
46 Xx Disorder Of Sex Development Induced By Maternal Derived Androgen C5680197
Chronic
3q26 Microduplication Syndrome C4755319
Chronic
Differing course
Communicable
46 Xx Disorder Of Sex Development Induced By Maternal Derived Androgen C5680197
No
3q26 Microduplication Syndrome C4755319
No
Different transmission
Body System
46 Xx Disorder Of Sex Development Induced By Maternal Derived Androgen C5680197
reproductive
3q26 Microduplication Syndrome C4755319
congenital
Same/different system
Category
46 Xx Disorder Of Sex Development Induced By Maternal Derived Androgen C5680197
endocrine
3q26 Microduplication Syndrome C4755319
genetic
Different category
Bottom line
46-xx-disorder-of-sex-development-induced-by-maternal-derived-androgen-C5680197 and 3q26-microduplication-syndrome-C4755319 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 46 Xx Disorder Of Sex Development Induced By Maternal Derived Androgen C5680197 | 3q26 Microduplication Syndrome C4755319 | Discriminating power |
|---|---|---|---|
| Genital development | May cause atypical external genital development in an XX fetus, ranging from mild to severe. | Not primarily defined by genital virilization; any genital findings depend on the duplicated genes. | High |
| Neurodevelopment | Global developmental delay is not established as a typical feature of androgen exposure alone. | Developmental delay and other features may occur, depending on the specific genes involved. | Moderate |
| Etiologic clue | History suggests androgens from the pregnant person reached the fetus. | A chromosomal copy-number change at 3q26 is the defining finding. | High |
When to favor each condition
Choose 46 Xx Disorder Of Sex Development Induced By Maternal Derived Androgen C5680197 when
XX newborn with atypical genitalia and a plausible maternal androgen source
The phenotype and exposure history align with the supplied endocrine mechanism.
Moderate
46,XX karyotype without a causal chromosomal duplication
Sex-chromosome result supports an XX DSD evaluation rather than a 3q26 diagnosis.
Moderate
Endocrine assessment points toward prenatal androgen exposure
Specialist interpretation is needed; no single cutoff is supplied here.
Low
Choose 3q26 Microduplication Syndrome C4755319 when
Developmental delay or congenital features with a detected 3q26 gain
The chromosomal finding directly supports the genetic condition.
High
Phenotype is not explained by maternal androgen exposure
A broader congenital or genetic evaluation is more appropriate.
Moderate
Family or prenatal testing identifies the same microduplication
Inheritance and variable expression require genetic counseling.
Moderate
How key tests differ
| Test | 46 Xx Disorder Of Sex Development Induced By Maternal Derived Androgen C5680197 | 3q26 Microduplication Syndrome C4755319 | Interpretation |
|---|---|---|---|
| Karyotype | 46,XX is expected in the named condition. | Sex chromosomes are not the defining abnormality. | A karyotype distinguishes chromosomal sex but does not prove either cause. |
| Chromosomal microarray | No causal 3q26 duplication is expected from the supplied description. | Extra material at 3q26 supports the diagnosis. | Gene content and clinical correlation determine significance. |
| Endocrine and exposure review | Maternal androgen source and timing are central clues. | Androgen studies do not establish the microduplication. | Abnormal results require clinician interpretation and are not themselves a diagnosis. |
Prognosis comparison
46 Xx Disorder Of Sex Development Induced By Maternal Derived Androgen C5680197
- Outcome
- Course may be chronic, but long-term outcome is not established here.
- Factors
- Degree of genital difference, timing of exposure, and specialist care may influence needs.
3q26 Microduplication Syndrome C4755319
- Outcome
- Often chronic with variable developmental impact; exact prognosis is not established.
- Factors
- Duplication size, genes involved, and associated findings may affect severity.
Time frame: From prenatal or congenital recognition through long-term follow-up.
Neither source provides mortality or definitive outcome rates; clinician interpretation is required.
Complications comparison
| Complication | Presentation |
|---|---|
| Genital and reproductive care | May require individualized hormone and surgical decisions guided by specialists. Genital complications are not established and depend on involved genes. Avoid routine assumptions; decisions require informed, multidisciplinary care. |
| Developmental needs | Developmental impairment is not established by the supplied description. Delays and learning or developmental support needs may occur. Assessment should follow observed development rather than the label alone. |
| Psychosocial impact | Sensitive communication about sex development and bodily difference is important. Families may need support for uncertainty and variable features. Both benefit from privacy, counseling, and coordinated follow-up. |
Patient education highlights
- HighDiagnosis is specific
An abnormal finding or test does not automatically prove either condition; ask which results support the label.
- HighIndividual care
Management, including any hormone or surgical discussion, should be specialist-led and individualized.
- MediumVariable outlook
Reliable prevalence, mortality, and exact outcome data are not established in the supplied source.